Rezolute to Participate in Upcoming Investor Conferences
Rezolute (Nasdaq: RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in three major upcoming investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference (September 3-5), the H.C. Wainwright Global Investment Conference (September 8-10), and the Morgan Stanley Global Healthcare Conference (September 8-10). Management will engage in Fireside Chats and one-on-one meetings with investors during these events.
Rezolute (Nasdaq: RZLT), azienda in fase avanzata specializzata nelle malattie rare e nello specifico nel trattamento dell'ipoglicemia dovuta a iperinsulinemia, ha annunciato la sua partecipazione a tre importanti conferenze per investitori previste per settembre 2025.
La società sarà presente al Cantor Global Healthcare Conference (3-5 settembre), al H.C. Wainwright Global Investment Conference (8-10 settembre) e al Morgan Stanley Global Healthcare Conference (8-10 settembre). Il management terrà Fireside Chats e incontri one-to-one con gli investitori durante questi eventi.
Rezolute (Nasdaq: RZLT), una compañía en fase avanzada dedicada a las enfermedades raras y al tratamiento de la hipoglucemia causada por hiperinsulinismo, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025.
La empresa asistirá a la Cantor Global Healthcare Conference (3-5 de septiembre), a la H.C. Wainwright Global Investment Conference (8-10 de septiembre) y a la Morgan Stanley Global Healthcare Conference (8-10 de septiembre). La dirección mantendrá Fireside Chats y reuniones uno a uno con inversores durante estos eventos.
Rezolute (Nasdaq: RZLT), 과다인슐린혈증으로 인한 저혈당 치료를 전문으로 하는 후기 단계 희귀질환 기업이 2025년 9월에 열리는 주요 투자자 콘퍼런스 세 곳에 참가한다고 발표했습니다.
회사는 Cantor Global Healthcare Conference(9월 3–5일), H.C. Wainwright Global Investment Conference(9월 8–10일), 그리고 Morgan Stanley Global Healthcare Conference(9월 8–10일)에 참석할 예정입니다. 경영진은 이들 행사에서 파이어사이드 채팅과 일대일 미팅을 통해 투자자들과 소통할 것입니다.
Rezolute (Nasdaq: RZLT), société en phase avancée spécialisée dans les maladies rares et le traitement de l'hypoglycémie due à l'hyperinsulinisme, a annoncé sa participation à trois grandes conférences investisseurs prévues en septembre 2025.
La société assistera à la Cantor Global Healthcare Conference (3-5 septembre), à la H.C. Wainwright Global Investment Conference (8-10 septembre) et à la Morgan Stanley Global Healthcare Conference (8-10 septembre). La direction tiendra des Fireside Chats et des rendez-vous individuels avec des investisseurs lors de ces événements.
Rezolute (Nasdaq: RZLT), ein spätphasiges Unternehmen für seltene Krankheiten, das sich auf die Behandlung von Hypoglykämie durch Hyperinsulinismus spezialisiert hat, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird an der Cantor Global Healthcare Conference (3.–5. September), der H.C. Wainwright Global Investment Conference (8.–10. September) und der Morgan Stanley Global Healthcare Conference (8.–10. September) teilnehmen. Das Management wird während dieser Veranstaltungen Fireside Chats und Einzelgespräche mit Investoren führen.
- None.
- None.
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Event: Cantor Global Healthcare Conference
Date: September 3-5, 2025
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8-10, 2025
Event: Morgan Stanley 23rd Annual Global Healthcare Conference
Date: September 8-10, 2025
Management will be participating in Fireside Chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Cantor, H.C. Wainwright, and Morgan Stanley representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
FAQ
When is Rezolute (RZLT) presenting at the Cantor Global Healthcare Conference 2025?
Which investor conferences will Rezolute (RZLT) attend in September 2025?
How can investors meet with Rezolute management at these conferences?
What is Rezolute's (RZLT) main business focus?
